Correlation Analysis Between Expression of Histone Deacetylase 6 and Clinical Parameters in IgA Nephropathy Patients

Overview

Journal Ren Fail

Publisher Informa Healthcare

Date 2021 Apr 26

PMID 33896334

Authors

Yan Hu

Minghua Shang

Yingfeng Shi

Min Tao

Weijie Yuan

Lunxian Tang

Xiaoyan Ma

Binbin Cui

Hui Chen

Xun Zhou

Shougang Zhuang

Na Liu

Affiliations

Soon will be listed here.

Abstract

Background: It has been demonstrated that histone deacetylase 6 (HDAC6) is involved in various kidney diseases in experimental study. However, correlation between HDAC6 and clinical parameters in IgA nephropathy (IgAN) patients is still unknown.

Methods: A total of 46 human kidney biopsy specimens with IgAN were selected as observation group, specimens of normal renal cortex tissue that was not affected by the tumor from patients with renal carcinoma ( = 7) served as control. We investigated the relationship between HDAC6 and clinical parameters in IgAN.

Results: HDAC6 was highly expressed in human kidney biopsy specimens with IgAN compared with control group, while the number of acetyl histone H3 positive cells were significantly decreased. There was a statistical difference in the indexes of albumin, estimated glomerular filtration rate (eGFR), serum urea, serum creatinine, serum uric acid, β2-microglobulin, cystatin C, cholesterol, high-density lipoprotein, low-density lipoprotein, and HDAC6 positive area among the different Oxford Classification ( < 0.05). The expression of HDAC6 was different in various eGFR levels, the expression of HDAC6 increased with the decreasing of eGFR level, the expression of acetyl histone H3 decreased with the decreasing of eGFR level. In addition, the expression of HDAC6 positively correlated with Masson trichrome positive area, serum urea, serum creatinine, β2 macroglobulin, and cystatin C, while negatively correlated with eGFR and acetyl histone H3. Multivariate linear regression analysis demonstrated that eGFR and cystatin C were independently associated with HDAC6, respectively ( < 0.05).

Conclusions: These results suggested that high level of HDAC6 expression in IgAN is correlated with renal dysfunction.

References

Harris R, Neilson E . Toward a unified theory of renal progression. Annu Rev Med. 2006; 57:365-80. DOI: 10.1146/annurev.med.57.121304.131342. View

Chen X, Yu C, Hou X, Li J, Li T, Qiu A . Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-β and EGFR signaling pathways in obstructive nephropathy. Am J Physiol Renal Physiol. 2020; 319(6):F1003-F1014. PMC: 7792693. DOI: 10.1152/ajprenal.00261.2020. View

Peters H, Waanders F, Meijer E, van den Brand J, Steenbergen E, Goor H . High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy. Nephrol Dial Transplant. 2011; 26(11):3581-8. DOI: 10.1093/ndt/gfr135. View

Yanda M, Liu Q, Cebotaru V, Guggino W, Cebotaru L . Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca in knock-out mouse models of polycystic kidney disease. J Biol Chem. 2017; 292(43):17897-17908. PMC: 5663887. DOI: 10.1074/jbc.M117.803775. View

Herzenberg A, Fogo A, Reich H, Troyanov S, Bavbek N, Massat A . Validation of the Oxford classification of IgA nephropathy. Kidney Int. 2011; 80(3):310-7. DOI: 10.1038/ki.2011.126. View

Palomo M, Vera M, Martin S, Torramade-Moix S, Martinez-Sanchez J, Belen Moreno A . Up-regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide. J Cell Mol Med. 2019; 24(2):1713-1723. PMC: 6991634. DOI: 10.1111/jcmm.14865. View

Trimarchi H, Barratt J, Cattran D, Cook H, Coppo R, Haas M . Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017; 91(5):1014-1021. DOI: 10.1016/j.kint.2017.02.003. View

Leeaphorn N, Garg N, Khankin E, Cardarelli F, Pavlakis M . Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database. Transpl Int. 2017; 31(2):175-186. PMC: 5762402. DOI: 10.1111/tri.13075. View

Shi Y, Xu L, Tang J, Fang L, Ma S, Ma X . Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury. Am J Physiol Renal Physiol. 2017; 312(3):F502-F515. PMC: 5374306. DOI: 10.1152/ajprenal.00546.2016. View

10.

Wang G, Kwan B, Lai F, Chow K, Kam-Tao Li P, Szeto C . Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis Markers. 2010; 28(2):79-86. PMC: 3833417. DOI: 10.3233/DMA-2010-0687. View

11.

Caron H, van Schaik B, van der Mee M, Baas F, Riggins G, van Sluis P . The human transcriptome map: clustering of highly expressed genes in chromosomal domains. Science. 2001; 291(5507):1289-92. DOI: 10.1126/science.1056794. View

12.

Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K . The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012; 82(7):790-6. PMC: 3443545. DOI: 10.1038/ki.2012.197. View

13.

Roberts I, Cook H, Troyanov S, Alpers C, Amore A, Barratt J . The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76(5):546-56. DOI: 10.1038/ki.2009.168. View

14.

Parmigiani R, Xu W, Venta-Perez G, Erdjument-Bromage H, Yaneva M, Tempst P . HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A. 2008; 105(28):9633-8. PMC: 2443817. DOI: 10.1073/pnas.0803749105. View

15.

Choi S, Ryu Y, Kee H, Cho S, Kim G, Cho J . Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes. Vascul Pharmacol. 2015; 72:130-40. DOI: 10.1016/j.vph.2015.04.006. View

16.

Cebotaru L, Liu Q, Yanda M, Boinot C, Outeda P, Huso D . Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease. Kidney Int. 2016; 90(1):90-9. PMC: 4912414. DOI: 10.1016/j.kint.2016.01.026. View

17.

West A, Johnstone R . New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124(1):30-9. PMC: 3871231. DOI: 10.1172/JCI69738. View

18.

Lee J, An J, Hwang J, Lee H, Lee J, Kim S . p38 MAPK activity is associated with the histological degree of interstitial fibrosis in IgA nephropathy patients. PLoS One. 2019; 14(3):e0213981. PMC: 6428396. DOI: 10.1371/journal.pone.0213981. View

19.

Hyndman K, Kasztan M, Mendoza L, Monteiro-Pai S . Dynamic changes in histone deacetylases following kidney ischemia-reperfusion injury are critical for promoting proximal tubule proliferation. Am J Physiol Renal Physiol. 2019; 316(5):F875-F888. PMC: 6580243. DOI: 10.1152/ajprenal.00499.2018. View

20.

Shi S, Wang S, Jiang L, Lv J, Liu L, Chen Y . Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification. Clin J Am Soc Nephrol. 2011; 6(9):2175-84. PMC: 3358999. DOI: 10.2215/CJN.11521210. View